Baidu
map

政府工作报告中医药人的“药点”

2018-03-05 佚名 米内网

1、社会养老保险覆盖9亿多人,基本医疗保险覆盖13.5亿人,织就了世界上最大的社会保障网。人均预期寿命达到76.7岁。


过去五年工作回顾

1、社会养老保险覆盖9亿多人,基本医疗保险覆盖13.5亿人,织就了世界上最大的社会保障网。人均预期寿命达到76.7岁。

2、多措并举降成本,压减政府性基金项目30%,削减中央政府层面设立的涉企收费项目60%以上,阶段性降低“五险一金”缴费比例,推动降低用能、物流、电信等成本。突出重点加大补短板力度。

3、建立统一的城乡居民基本养老、医疗保险制度,实现机关事业单位和企业养老保险制度并轨。出台划转部分国有资本充实社保基金方案。实施医疗、医保、医药联动改革,全面推开公立医院综合改革,取消长期实行的药品加成政策,药品医疗器械审批制度改革取得突破。

4、居民基本医保人均财政补助标准由240元提高到450元,大病保险制度基本建立、已有1700多万人次受益,异地就医住院费用实现直接结算,分级诊疗和医联体建设加快推进。持续合理提高退休人员基本养老金。提高低保、优抚等标准,完善社会救助制度,近6000万低保人员和特困群众基本生活得到保障。

5、在空气质量、环境卫生、食品药品安全和住房、教育、医疗、就业、养老等方面,群众还有不少不满意的地方。

对2018年政府工作的建议

1、深入推进供给侧结构性改革。坚持把发展经济着力点放在实体经济上,继续抓好“三去一降一补”,大力简政减税减费,不断优化营商环境,进一步激发市场主体活力,提升经济发展质量。

2、加强国家创新体系建设。强化基础研究和应用基础研究,启动一批科技创新重大项目,高标准建设国家实验室。鼓励企业牵头实施重大科技项目,支持科研院所、高校与企业融通创新,加快创新成果转化应用。国家科技投入要向民生领域倾斜,加强雾霾治理、癌症等重大疾病防治攻关,使科技更好造福人民。

3、推进国资国企改革。制定出资人监管权责清单。深化国有资本投资、运营公司等改革试点,赋予更多自主权。继续推进国有企业优化重组和央企股份制改革,加快形成有效制衡的法人治理结构和灵活高效的市场化经营机制,持续瘦身健体,提升主业核心竞争力,推动国有资本做强做优做大。稳妥推进混合所有制改革。落实向全国人大常委会报告国有资产管理情况的制度。国有企业要通过改革创新,走在高质量发展前列。

4、推进社会体制改革。深化养老保险制度改革,建立企业职工基本养老保险基金中央调剂制度。深化公立医院综合改革,协调推进医疗价格、人事薪酬、药品流通、医保支付改革,提高医疗卫生服务质量,下大力气解决群众看病就医难题。深入推进教育、文化、体育等改革,充分释放社会领域巨大发展潜力。

5、增强消费对经济发展的基础性作用。推进消费升级,发展消费新业态新模式。将新能源汽车车辆购置税优惠政策再延长三年,全面取消二手车限迁政策。支持社会力量增加医疗、养老、教育、文化、体育等服务供给。创建全域旅游示范区,降低重点国有景区门票价格。推动网购、快递健康发展。对各类侵害消费者权益的行为,要依法惩处、决不姑息。

6、促进外商投资稳定增长。加强与国际通行经贸规则对接,建设国际一流营商环境。全面放开一般制造业,扩大电信、医疗、教育、养老、新能源汽车等领域开放。有序开放银行卡清算等市场,放开外资保险经纪公司经营范围限制,放宽或取消银行、证券、基金管理、期货、金融资产管理公司等外资股比限制,统一中外资银行市场准入标准。实施境外投资者境内利润再投资递延纳税。简化外资企业设立程序,商务备案与工商登记“一口办理”。全面复制推广自贸区经验,探索建设自由贸易港,打造改革开放新高地。

7、实施健康中国战略。提高基本医保和大病保险保障水平,居民基本医保人均财政补助标准再增加40元,一半用于大病保险。扩大跨省异地就医直接结算范围,把基层医院和外出农民工、外来就业创业人员等全部纳入。加强全科医生队伍建设,推进分级诊疗。继续提高基本公共卫生服务经费人均财政补助标准。改善妇幼保健服务。支持中医药事业传承发展。创新食品药品监管方式,注重用互联网、大数据等提升监管效能,加快实现全程留痕、信息可追溯,让问题产品无处藏身、不法制售者难逃法网,让消费者买得放心、吃得安全。做好北京冬奥会、冬残奥会筹办工作,多渠道增加全民健身场所和设施。人民群众身心健康、向善向上,国家必将生机勃勃、走向繁荣富强。

8、强化民生兜底保障。稳步提高城乡低保、社会救助、抚恤优待等标准。积极应对人口老龄化,发展居家、社区和互助式养老,推进医养结合,提高养老院服务质量。做好军烈属优抚工作。加强残疾人康复服务。健全社会救助体系,支持公益慈善事业发展。倾情倾力做好托底工作,不因事难而推诿,不因善小而不为,要让每一个身处困境者都能得到社会的关爱和温暖。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046482, encodeId=5ece20464828d, content=<a href='/topic/show?id=e5d74e881ff' target=_blank style='color:#2F92EE;'>#工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47881, encryptionId=e5d74e881ff, topicName=工作报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Jun 12 10:45:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409387, encodeId=1fea140938ece, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449918, encodeId=cb56144991865, content=<a href='/topic/show?id=bf3e5e46080' target=_blank style='color:#2F92EE;'>#政府工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57460, encryptionId=bf3e5e46080, topicName=政府工作报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4b15523194, createdName=minlingfeng, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469593, encodeId=841b1469593fc, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293251, encodeId=6d91293251d2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 05 14:27:01 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046482, encodeId=5ece20464828d, content=<a href='/topic/show?id=e5d74e881ff' target=_blank style='color:#2F92EE;'>#工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47881, encryptionId=e5d74e881ff, topicName=工作报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Jun 12 10:45:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409387, encodeId=1fea140938ece, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449918, encodeId=cb56144991865, content=<a href='/topic/show?id=bf3e5e46080' target=_blank style='color:#2F92EE;'>#政府工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57460, encryptionId=bf3e5e46080, topicName=政府工作报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4b15523194, createdName=minlingfeng, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469593, encodeId=841b1469593fc, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293251, encodeId=6d91293251d2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 05 14:27:01 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-07 hb2008ye
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046482, encodeId=5ece20464828d, content=<a href='/topic/show?id=e5d74e881ff' target=_blank style='color:#2F92EE;'>#工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47881, encryptionId=e5d74e881ff, topicName=工作报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Jun 12 10:45:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409387, encodeId=1fea140938ece, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449918, encodeId=cb56144991865, content=<a href='/topic/show?id=bf3e5e46080' target=_blank style='color:#2F92EE;'>#政府工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57460, encryptionId=bf3e5e46080, topicName=政府工作报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4b15523194, createdName=minlingfeng, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469593, encodeId=841b1469593fc, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293251, encodeId=6d91293251d2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 05 14:27:01 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046482, encodeId=5ece20464828d, content=<a href='/topic/show?id=e5d74e881ff' target=_blank style='color:#2F92EE;'>#工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47881, encryptionId=e5d74e881ff, topicName=工作报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Jun 12 10:45:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409387, encodeId=1fea140938ece, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449918, encodeId=cb56144991865, content=<a href='/topic/show?id=bf3e5e46080' target=_blank style='color:#2F92EE;'>#政府工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57460, encryptionId=bf3e5e46080, topicName=政府工作报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4b15523194, createdName=minlingfeng, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469593, encodeId=841b1469593fc, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293251, encodeId=6d91293251d2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 05 14:27:01 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046482, encodeId=5ece20464828d, content=<a href='/topic/show?id=e5d74e881ff' target=_blank style='color:#2F92EE;'>#工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47881, encryptionId=e5d74e881ff, topicName=工作报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Jun 12 10:45:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409387, encodeId=1fea140938ece, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449918, encodeId=cb56144991865, content=<a href='/topic/show?id=bf3e5e46080' target=_blank style='color:#2F92EE;'>#政府工作报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57460, encryptionId=bf3e5e46080, topicName=政府工作报告)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4b15523194, createdName=minlingfeng, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469593, encodeId=841b1469593fc, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Wed Mar 07 04:45:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293251, encodeId=6d91293251d2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 05 14:27:01 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-05 131****1460

    学习了受益匪浅

    0

Baidu
map
Baidu
map
Baidu
map